Non Small Cell Lung Cancer News and Research RSS Feed - Non Small Cell Lung Cancer News and Research

Non-Small Cell Lung Cancers are a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.
Current smokers at increased risk of developing SPLC

Current smokers at increased risk of developing SPLC

Non-small cell lung cancer (NSCLC) survivors who never smoked or who are former smokers at the time of diagnosis have a lower risk of developing secondary primary lung cancers (SPLC) compared to those who are current smokers, suggesting that increased tobacco exposure is associated with a higher risk of SPLC, according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting. [More]
EnGeneIC receives award from Cancer Institute NSW for groundbreaking cancer research

EnGeneIC receives award from Cancer Institute NSW for groundbreaking cancer research

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, announced that, together with the Asbestos Disease Research Institute, it has received the 2014 Cancer Institute New South Wales Premier’s Award for Excellence in Translational Cancer Research. [More]
Cancer Research UK, CRT partner with Asterias to trail novel immunotherapy treatment for lung cancer

Cancer Research UK, CRT partner with Asterias to trail novel immunotherapy treatment for lung cancer

CANCER RESEARCH UK and Cancer Research Technology , the charity's development and commercialisation arm, have reached an agreement with Asterias Biotherapeutics, Inc., a biotechnology company in the emerging field of regenerative medicine, to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in subjects with non-small cell lung cancer. [More]
UT Southwestern faculty awarded CPRIT grants to combat cancer

UT Southwestern faculty awarded CPRIT grants to combat cancer

UT Southwestern Medical Center faculty have received 19 grants totaling more than $26 million from the Cancer Prevention and Research Institute of Texas to expand cancer screenings, investigate the effectiveness and viability for cancer therapies and radiation treatments, conduct research into cancer biology, and recruitment. [More]
Scientists explore ways to personalise radiotherapy dose given to lung cancer patients

Scientists explore ways to personalise radiotherapy dose given to lung cancer patients

Manchester scientists are working out how to safely increase the radiotherapy dose given to lung cancer patients - potentially offering improved local control and survival. [More]
Spring Bioscience launches PD-L1 (SP142) rabbit monoclonal immunohistochemistry antibody1

Spring Bioscience launches PD-L1 (SP142) rabbit monoclonal immunohistochemistry antibody1

Spring Bioscience (Spring), a member of the Roche Group, today announced the launch of its PD-L1 (SP142) rabbit monoclonal immunohistochemistry (IHC) antibody. [More]
Researchers examine impact of BIM deletion on survival outcomes of advanced NSCLC patients

Researchers examine impact of BIM deletion on survival outcomes of advanced NSCLC patients

Bcl-2-like protein 11 (BIM) deletion in advanced non-small cell lung cancer (NSCLC) is associated with shorter progression free survival (PFS) in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) or chemotherapy treated Asian patients. [More]
Researchers identify mutated forms of gene that encodes unregulated enzyme driving CML

Researchers identify mutated forms of gene that encodes unregulated enzyme driving CML

Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have identified and characterized mutated forms of the gene that encodes BCR-ABL, the unregulated enzyme driving the blood cancer chronic myeloid leukemia (CML). [More]
Seven physicians receive ASTRO grants to advance radiation oncology research

Seven physicians receive ASTRO grants to advance radiation oncology research

The American Society for Radiation Oncology has selected seven leading physicians to receive a total of $675,000 in awards and grants to advance radiation oncology research. The ASTRO Junior Faculty Career Research Training Award, the ASTRO Residents/Fellows in Radiation Oncology Research Seed Grant and the ASTRO/Radiation Oncology Institute Comparative Effectiveness Research Award will fund studies in radiation and cancer biology, radiation physics, translational research, outcomes/health services research and comparative effectiveness research within radiation oncology. [More]
Oncothyreon acquires Alpine Biosciences to enable targeted delivery of multiple therapeutic agents

Oncothyreon acquires Alpine Biosciences to enable targeted delivery of multiple therapeutic agents

Oncothyreon Inc., a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that it has acquired Alpine Biosciences, Inc., of Seattle, Washington, a privately held biotechnology company developing protocells, a nanoparticle platform technology designed to enable the targeted delivery of multiple therapeutic agents, including nucleic acids, proteins, peptides and small molecules. [More]
EMD Serono begins MSB0010718C Phase II study in mMCC patients

EMD Serono begins MSB0010718C Phase II study in mMCC patients

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the initiation of an international Phase II study designed to assess the efficacy and safety of MSB0010718C, an investigational fully human IgG1 monoclonal antibody that binds to programmed death-ligand 1 (PD-L1). [More]
Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS). [More]

Prognostic value of visceral plural invasion limited in part-solid lung cancer

Visceral plural invasion is a significant predictor of survival in patients with small solid lung tumours but not in patients with part-solid tumours, Japanese study findings indicate. [More]
Combined risk score enhances radiation pneumonitis prediction

Combined risk score enhances radiation pneumonitis prediction

Combining dose-volume histogram parameters with age and baseline pulmonary fibrosis score creates a novel predictive risk score that improves prediction of radiation pneumonitis in patients receiving concurrent chemoradiotherapy for non-small-cell lung cancer, research shows. [More]
Co-targeting strategies suggested for EGFR-TKI resistance in NSCLC

Co-targeting strategies suggested for EGFR-TKI resistance in NSCLC

Researchers have identified additional resistance mechanisms that could be targeted to improve the efficacy of irreversible epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small-cell lung cancer harbouring both EGFR and T790M mutations. [More]

CRIPTO1 role in TKI resistance elucidated

Overexpression of CRIPTO1 may explain intrinsic tyrosine kinase inhibitor resistance in around 10% of patients with non-small-cell lung cancer and endothelial growth factor receptor mutations, research indicates. [More]
ROS1 fusion genes found in young East Asian patients with lung adenocarcinoma

ROS1 fusion genes found in young East Asian patients with lung adenocarcinoma

ROS1 fusion genes were successfully detected independent of gender or smoking history in young East Asian patients with lung adenocarcinoma, a histological subgroup in non-small cell lung cancer (NSCLC), using multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) and immunohistochemistry (IHC) diagnostic tests. [More]

TAZ represents a novel therapeutic target in NSCLC

Patients with non-small-cell lung cancer who express high levels of transcriptional coactivator with PDZ-binding motif may be a clinically distinct subgroup with an unfavourable prognosis, researchers report. [More]
CIP2A pathway involved in erlotinib response

CIP2A pathway involved in erlotinib response

Researchers have identified a novel mechanism, involving the cancerous inhibitor of protein phosphatase 2A pathway, which mediates the anti-tumour effects of erlotinib in non-small-cell lung cancer cells without epidermal growth factor receptor mutations. [More]
Chemoprevention and colon cancer: an interview with Dr. John Letterio, Case Western Reserve University School of Medicine

Chemoprevention and colon cancer: an interview with Dr. John Letterio, Case Western Reserve University School of Medicine

The basic idea of cancer chemopre­vention is to arrest or reverse the progression of pre­malignant cells towards full malignancy, using physiological mechanisms that do not kill healthy cells. [More]